

NUVAXOVID: POWERFUL AGAINST COVID-19, GENTLE ON PATIENTS.¹

The non-mRNA COVID-19 Vaccine With Manageable Side Effects.^{1*}

NUVAXOVID is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). NUVAXOVID is approved for use in individuals who are:

- 65 years of age and older, or
- 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

NUVAXOVID is the ONLY non-mRNA, protein-based COVID-19 vaccine^{1,2}



Protein-based

NUVAXOVID directly provides the protein needed for antibody production^{1,2}



Recombinant

Developed using technology already present in modern flu vaccines^{1,3}



Adjuvanted

The potent adjuvant provides a robust and enhanced immune response^{1,4}

What makes NUVAXOVID different from mRNA COVID-19 vaccines?

How NUVAXOVID Builds Immunity²:

STEP 1

Spike proteins contained in the vaccine are recognized by the immune system

STEP 2

Immune system produces antibodies and activates other immune cells

How mRNA Vaccines Build Immunity²:

STEP 1

mRNA uses cells' machinery to make the spike protein

STEP 2

Cells display spike protein antigens on their surface, where it is recognized by the immune system

STEP 3

Immune system produces antibodies and activates other immune cells

Who can receive NUVAXOVID?

Patients aged 65+ AND patients aged 12–64 who have ≥1 underlying condition that puts them at high risk for severe outcomes from COVID-19. NUVAXOVID can be used as a primary series OR seasonal dose following vaccination with any approved COVID-19 vaccine.¹

*In the pivotal clinical trial, most common side effects were mild-to-moderate and <0.1% of patients experienced Grade 4 solicited adverse reactions.¹

**CPT Code
91304**

Use this CPT code when administering NUVAXOVID to ensure you receive proper payment. This CPT code is unique to NUVAXOVID – the ONLY non-mRNA COVID-19 vaccine.^{1,2}

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

Do not administer NUVAXOVID to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of NUVAXOVID or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of NUVAXOVID

Please see additional Important Safety Information on back page.
Please see the full Prescribing Information [here](#).



COULD OFFERING YOUR PATIENTS A non-mRNA COVID-19 VACCINE MAKE THE DIFFERENCE?

NUVAXOVID OFFERS POWERFUL PROTECTION AGAINST COVID-19^{1,5}

~90%

Efficacy preventing COVID-19 in the pivotal trial

Primary endpoint: efficacy in preventing PCR-confirmed symptomatic mild, moderate, or severe COVID-19 from 7 days after the second dose.

(95% CI: 82.5, 93.8; $p < 0.001$) N=25,510

ZERO NUVAXOVID PATIENTS HAD MODERATE-TO-SEVERE COVID-19 ILLNESS^{1,5}

100%

Protection from moderate-to-severe COVID-19[†]

Secondary endpoint: efficacy in preventing moderate-to-severe disease from then-circulating strains of virus.

(95% CI: 87.0, 100.0) N=25,452

The NUVAXOVID vaccine may not protect all participants.

Pivotal Trial Study Design: Phase 3, multicenter, randomized, observer-blinded, placebo-controlled clinical trial evaluating efficacy and safety in 29,943 adults aged 18 and older. Participants were stratified by age (18 to 64 years and ≥ 65 years) and assigned in a 2:1 ratio to receive NUVAXOVID or placebo. Data based on strains circulating at time of study^{1,5}

[†]Moderate disease was defined as high fever and objective evidence of lower respiratory tract infection. Severe COVID-19 was defined as the presence of clinically significant tachypnea, tachycardia, or hypoxia; receipt of intensive respiratory support; major dysfunction of one or more organ systems; admission to an intensive care unit; or death.⁵

NUVAXOVID had low reactogenicity and minimal disruptive side effects¹

In the pivotal clinical trial, the majority of adverse events were Grade 1 or 2 and did not prevent daily activities. Higher severity reactions (Grade 4) were experienced by $\leq 0.1\%$ of patients for each of the most frequent solicited adverse reactions.¹



Discover more about the efficacy and tolerability of NUVAXOVID

INDICATION

NUVAXOVID is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). NUVAXOVID is approved for use in individuals who are:

- 65 years of age and older, or
- 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

Do not administer NUVAXOVID to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of NUVAXOVID or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of NUVAXOVID

MANAGEMENT OF ACUTE ALLERGIC REACTIONS

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of NUVAXOVID

MYOCARDITIS AND PERICARDITIS

Clinical trials data provide evidence for increased risks of myocarditis and pericarditis following administration of NUVAXOVID. There have been post-marketing reports of myocarditis and pericarditis following administration of NUVAXOVID

Please see the full Prescribing Information [here](#).

References: 1. Nuvaxovid. Prescribing Information. Novavax, Inc. 2. Centers for Disease Control and Prevention. Understanding how COVID-19 vaccines work. September 2024. Accessed September 18, 2025. https://www.cdc.gov/covid/vaccines/how-they-work.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvaccines%2Fdifferent-vaccines%2Fhow-they-work.html 3. Cid R, Bolívar J. Platforms for production of protein-based vaccines: from classical to next-generation strategies. *Biomolecules*. 2021;11(8):1072. doi: 10.3390/biom11081072 4. Bengtsson KL, Song H, Stertman L, et al. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. *Vaccine*. 2016;34(16):1927-1935. doi:10.1016/j.vaccine.2016.02.033 5. Dunkle LM, Kotloff KL, Gay CL, et al; 2019nCoV-301 Study Group. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. *N Engl J Med*. 2022;386(6):531-543. doi: 10.1056/NEJMoa2116185

SYNCOPE

Syncope (fainting) may occur in association with administration of injectable vaccines, including NUVAXOVID. Procedures should be in place to avoid injury from fainting

ALTERED IMMUNOCOMPETENCE

Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to NUVAXOVID

NUVAXOVID may not protect all vaccine recipients

COMMON ADVERSE REACTIONS

The most commonly reported (>10%) solicited adverse reactions included: injection site pain/tenderness, fatigue/malaise, muscle pain, headache, nausea/vomiting, fever, and joint pain



MAT-US-2505042-v2.0-09/2025 © 2025 Sanofi
Sanofi | Discovery Drive, Swiftwater, Pennsylvania 18370 | www.sanofi.us



Vaccine Code

CPT^{®a} differentiates COVID-19^b vaccines. Be sure to verify that your systems are correctly billing for the COVID-19 vaccine that you are using in your practice.

CPT code **91304** should be used to bill for Nuvaxovid. This code specifically describes this recombinant protein-based, non-mRNA COVID-19 vaccine. COVID-19 is a 1-component vaccine.

CPT Code	Code Description
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponinbased adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use.
Source: 2025 Current Procedural Terminology - all code descriptions are as defined by the American Medical Association.	

National Drug Codes (NDCs)

Some payers require an NDC in addition to the CPT code for the product. In such cases, it is important to format the NDC correctly, or the claim will be denied, and you will need to resubmit a corrected claim in order to be reconsidered for payment. Begin by determining if the payer requires the carton NDC or the unit-of-use NDC. On line 24A, place qualifier N4, the 11-digit NDC number (without hyphens), the Unit-of-Measure, and Units Dispensed. To convert the Nuvaxovid NDC to the required 11-digit format, add a leading zero in the middle section of numbers (ex. 80631-207-10 = 80631-0207-10). Unit-of-Measure, ML, is reported when the product is supplied in a liquid format. Units Dispensed is the actual decimal quantity administered. Continue to bill CPT code 91304 and the administration code. Below is how to submit the NDCs for Nuvaxovid.

When the Payer Requires the Carton NDC	When the Payer Requires the Unit-of-Use NDC	Description
N480631020710 ML0.5	N480631020701 ML0.5	Package of 10 single-dose syringes (10x1)

CVX and MVX Codes

CVX and MVX codes are used to populate immunization registries. The CVX code indicates which product was used, and the MVX code indicates the manufacturer of the product. When an MVX (manufacturer) code is paired with a CVX (vaccine administered) code, the specific trade-named vaccine can be identified. The CVX code for Nuvaxovid is 313 (COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5mcg/0.5 mL). The MVX code for Novavax is NVX.

INDICATION

NUVAXOVID is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults 65 years and older

NUVAXOVID is also indicated for individuals 12 through 64 years who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19

NUVAXOVID may not protect all vaccine recipients

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

Do not administer NUVAXOVID to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of NUVAXOVID or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of NUVAXOVID

Please see additional Important Safety Information continued on [page 3](#).

Administration Code For COVID-19 Vaccine

The administration of COVID-19 vaccine is reported in addition to the vaccine product code (ie, assign the code for the vaccine along with the appropriate code for its administration). Assign the appropriate immunization administration code based on the documentation in the medical record. To appropriately code for administration of a COVID-19 vaccine, bill 1 unit of CPT code 90480. See the grid below for more information on this code.

CPT Code	Code Description	Suggested Use
90480	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose	Appropriate coding for administration of a COVID-19 vaccine, for all age patients, with or with qualified counseling, is 1 unit of CPT 90480.

Source: 2025 Current Procedural Terminology - all code descriptions are as defined by the American Medical Association.

Diagnosis Codes (ICD-10-CM)^c

Below are suggested diagnosis codes that may be appropriate when submitting claims for a vaccine and its administration. Link the ICD-10 to both the vaccine and the administration service. If the vaccine is administered because of a specific diagnosis, the specific diagnosis code should be reported. Assign the appropriate code based on review of the documentation in the medical record.

ICD-10-CM Code	Code Description	Suggested Use
Z23	Encounter for immunization	When administered for active immunization
ICD-10 code specific to condition	To be determined by practitioner	When administered because of a diagnosis

Source: 2025 International Classification of Diseases, 10th Revision, Clinical Modification

Billing for a Visit and a Vaccination

If a vaccination is the only service provided, a visit is not billed. When a separate and significant visit is provided along with a vaccination, bill for the visit and the vaccination services. When a vaccine is administered at any type of visit, the modifier -25 may need to be attached to the visit code along with an ICD-10 code, which describes the reason for the visit, to identify that it is separate and significantly different than other services billed. As usual, code for the vaccine and the administration service using the appropriate CPT codes and the ICD-10 code(s) that identify the reason for the vaccination. Check with your payers to confirm their requirements regarding the use of the -25 modifier.

Do you have questions on coverage or payment for Sanofi products? Contact a Sanofi Reimbursement Specialist (RS). Call 1-800-VACCINE (1-800-822-2463) and choose the prompt for the RS.

Visit the Reimbursement Page on [VaccineShop.com](https://www.vaccine-shop.com)[®] for additional coding resources for Sanofi products.

Visit www.crackingthecodestraining.com for on-demand coding and billing videos and resources for Sanofi products.

Billing Example

A patient is seen at the physician's office for a follow-up exam. The physician recommends that she receive a dose of Nuvaxovid. The physician counsels on the vaccine component. The patient's plan requires NDCs on claims.

21. DIAGNOSIS OR NATURE OF ILLNESS (ITEM 24E BY LINE)		24. A N48063120710 ML0.5		B	C	D		UNIT	PLAN
1.	2.	From	To	Place of Service	Type of Service	PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances)	MODIFIER		
MM	DD	YY	MM	DD	YY	CPT/HCPCS			
11	25	25	11	25	25	11	99213	25	1
11	25	25	11	25	25	11	91304		2
							90480		2

Annotations:

- The ICD-10 code attached to the office visit must describe the reason for the visit. (Points to J45.909)
- Code the applicable level of office visit and use modifier -25 to alert the payer that the office visit is separate and significantly different than the other procedures performed, per the payer's coding requirements. (Points to 99213 25)
- Use CPT code 91304 for Nuvaxovid and because this is a COVID vaccine, bill for administration using 1 unit of CPT 90480. Link both codes to diagnosis code Z23. (Points to 91304 and 90480)
- The payer-required carton NDC number is included on line 24A. (Points to N48063120710 ML0.5)

IMPORTANT SAFETY INFORMATION [CONTINUED]

MANAGEMENT OF ACUTE ALLERGIC REACTIONS

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of NUVAXOVID

MYOCARDITIS and PERICARDITIS

Clinical trials data provide evidence for increased risks of myocarditis and pericarditis following administration of NUVAXOVID. There have been post-marketing reports of myocarditis and pericarditis following administration of NUVAXOVID

SYNCOPE

Syncope (fainting) may occur in association with administration of injectable vaccines, including NUVAXOVID. Procedures should be in place to avoid injury from fainting

ALTERED IMMUNOCOMPETENCE

Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to NUVAXOVID

COMMON ADVERSE REACTIONS

The most commonly reported (> 10%) solicited adverse reactions included: injection site pain/tenderness, fatigue/malaise, muscle pain, headache, nausea/vomiting, fever, and joint pain.

Please see [Prescribing Information](#) for Nuvaxovid.

^a CPT (Current Procedural Terminology) is a registered trademark of the American Medical Association; ^b COVID-19 = Coronavirus disease of 2019; ^c ICD-10 = International Classification of Diseases, 10th Revision.

The information contained in this Coding & Billing Sheet is provided for informational purposes only. Every reasonable effort has been made to verify the accuracy of the information; however, this quick reference is not intended to provide specific guidance on how to utilize, code, bill, or charge for any product or service. Health care providers should make the ultimate decision as to when to use a specific product based on clinical appropriateness for a particular patient. Third-party payment for medical products and services is affected by numerous factors, and Sanofi Inc. cannot guarantee success in obtaining insurance payments.